Melinta Therapeutics (Formerly known as Rib-X Pharmaceuticals, Inc.)
132 articles with Melinta Therapeutics (Formerly known as Rib-X Pharmaceuticals, Inc.)
Melinta Therapeutics Announces Appointment of Christine Ann Miller as President and Chief Executive Officer
Melinta Therapeutics, Inc. (“Melinta”), a commercial-stage company focused on the development and commercialization of novel antibiotics, today announced that its Board of Directors has appointed Christine Ann Miller as President and Chief Executive Officer and member of the board, effective August 3, 2020. In April of this year, Melinta became privately owned by affiliates of healthcare investment firm Deerfield Management Company, L.P. (“
Melinta Therapeutics Announces Termination of Merger Agreement and Tender Offer for Shares of Tetraphase
Melinta Therapeutics, Inc. (“Melinta”), a commercial-stage antibiotics company, announced that on June 24, 2020, pursuant to the Agreement and Plan of Merger by and among Melinta, Toronto Transaction Corp. (“Purchaser”) and Tetraphase Pharmaceuticals, Inc. (“Tetraphase”) dated as of June 4, 2020 (the “Merger Agreement”), it had terminated the previously announced cash tender offer to acquire all of the outstanding shares of common stock of Tetraphase (the “Offer”).
Melinta Therapeutics, Inc. (“Melinta”), a commercial-stage antibiotics company, announced that on June 4, 2020, it entered into a definitive merger agreement with Tetraphase Pharmaceuticals, Inc. (“Tetraphase”) pursuant to which Melinta would acquire Tetraphase,
June 4, 2020 13:22 UTC Tetraphase terminates merger agreement with AcelRx to enter into merger agreement with Melinta Melinta agreement provides for an aggregate of $39.0 million upfront in cash plus potential contingent value rights cash payments of up to $16.0 million Acquisition Expected to Close in early Q3 2020 WATERTOWN, Mass.--( BUSINESS WIRE )-- Tetraphase Pharmaceuticals, Inc. (Nasdaq: TTPH), a biopharmaceutical company focused on commercializing its
Tetraphase Announces Receipt of Amended Melinta Proposal, Determination of Superior Offer and Notice to AcelRx
Tetraphase Pharmaceuticals, Inc. announced that its Board of Directors has received a revised proposal from Melinta Therapeutics, Inc. amending its prior proposal to acquire the Company, and has determined that the Amended Melinta Proposal is a “Superior Offer” under the terms of the Agreement and Plan of Merger, dated March 15, 2020 and amended on May 27, 2020, to which the Company is a party with AcelRx Pharmaceuticals, Inc. and its merger subsidiary.
Tetraphase Pharmaceuticals, Inc. (Nasdaq:TTPH), a biopharmaceutical company focused on commercializing its novel tetracycline Xerava™ (eravacycline for injection) to treat serious and life-threatening infections, today announced that its Board of Directors has determined that the latest proposal from Melinta Therapeutics, Inc
Company is Well-Positioned for Success as it Emerges from Chapter 11 In Partnership with Deerfield, Plans for Growth are Announced NEW YORK--( BUSINESS WIRE )-- Commercial-stage antibiotics company Melinta Therapeutics (“Melinta”) and healthcare investment firm Deerfield Management Company, L.P. (“Deerfield”), announced today that Melinta has successfully completed its financial restructuring and has emerged from Chapter 11. In accordanc
Deerfield Management placed Melinta’s assets up for auction, but no other companies made competing bids, leaving Deerfield in control of the company’s assets.
Melinta Therapeutics Confirms Deerfield as Successful Bidder for CompanyCompany Poised to Emerge on Financially Sound Footing Ensuring Continued Availability of Company’s Products and Related Support
Melinta Therapeutics, Inc. (the “Company” or “Melinta”), a commercial-stage company focused on the development and commercialization of novel antibiotics to treat serious bacterial infections, confirmed today that the Company’s agreement with funds managed by Deerfield Management Company, L.P.,
Company Previously Announced Agreement of its Secured Lenders to Acquire Company as Going Concern, Subject to Higher and Better Offers
Melinta Therapeutics Announces Restructuring Support Agreement with its Secured Lenders under its Senior Credit Facility
Company Initiates Voluntary Chapter 11 Process to Effectuate Restructuring Transaction While Continuing Normal-Course Operations
The Company encourages its current and potential investors to read this quarterly report for information related to our third quarter 2019 financial results and other important corporate updates.
Melinta Therapeutics Announces U.S. FDA Approval of Supplemental New Drug Application for BAXDELA® (delafloxacin) for the Treatment of Community-Acquired Bacterial Pneumonia (CABP)
Melinta Therapeutics, Inc. (NASDAQ: MLNT), a commercial-stage company focused on the development and commercialization of novel antibiotics to treat serious bacterial infections, today announced the U.S. Food and Drug Administration (FDA) has approved BAXDELA® (delafloxacin) for the treatment of adult patients with community-acquired bacterial pneumonia (CABP) caused by designated susceptible bacteria.
There’s clearly a need for new antibiotics to fight infections. If so, why are so many companies in the space abandoning it or going out of business?
Hikma Pharmaceuticals PLC (Hikma, Group) (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY) (rated Ba1 Moody’s / BB+ S&P, both stable) announces an exclusive license, supply and distribution agreement with Melinta Therapeutics (Melinta), for Melinta’s intravenous and oral formulations of Baxdela
An Antibiotic with Both Orphan Drug and Qualified Infectious Disease Product (QIDP) Designations
1/4/2019Biopharma companies begin 2019 with a flurry of hiring to fill executive leadership spots, including Dermavant, UroGen, Melinta, Translate Bio, and more.
12/26/2018Companies closed out the year with a number of appointments and hires to strengthen their leadership teams, including changes at the FDA, Melinta, CLSA, Virion, and more.
Melinta Therapeutics Announces Positive Top-Line Results in Phase III Trial of Baxdela® (delafloxacin) for Treatment of CABP
Met primary endpoint of Early Clinical Response at 96 hours after the first dose
Qpex Biopharma, a company spun-out of The Medicines Company focused on the development of anti-infective assets, launched this morning supported by a $33 million Series A financing round and a BARDA contract worth up to $132 million.